Pre-made Flanvotumab benchmark antibody ( Whole mAb, anti-TYRP1 therapeutic antibody, Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-216

Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-216-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Flanvotumab biosimilar, Whole mAb, Anti-TYRP1 Antibody: Anti-TRP/CAS2/CATB/GP75/OCA3/TRP1/TYRP/b-PROTEIN therapeutic antibody
INN Name Flanvotumab
TargetTYRP1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesImClone Systems;Eli Lilly
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMalignant melanoma
Development Techna